Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation (Nasdaq: LFVN) is a health and wellness company centered on nutrigenomics and cellular activation, and its news flow reflects this focus. The company regularly issues updates on its activator-based product portfolio, consultant community, scientific research, and participation in investor and industry events. As the Activation company, LifeVantage highlights how its products, such as the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, and the comprehensive gut activator P84, fit into broader wellness systems and scientific narratives.
News about LifeVantage often covers new product launches and enhancements, including additions to its activation-supporting nutrients, AXIO nootropic energy drink mixes, and TrueScience skin and hair care line. Company communications also describe major field events like Momentum Academy and Global Kickoff, where Consultants receive training, hear about new tools, and learn strategies related to enrollment, retention, and advancement. These events frequently coincide with the introduction of new offerings or the integration of acquired product lines such as LoveBiome’s P84.
Investors following LFVN can also expect announcements on quarterly and annual financial results, dividend declarations, share repurchase activity, and guidance ranges, as well as notices of participation in conferences and fireside chats. The company’s releases include commentary from management on strategic initiatives such as integrating LoveBiome assets, expanding its wellness ecosystem, and advancing digital capabilities like the Daily Activation app.
This news page aggregates these updates so readers can track developments in LifeVantage’s product science, consultant network, and corporate strategy in one place. For anyone monitoring LFVN stock, the consultant-driven business model, or trends in nutrigenomics-focused wellness products, the news feed provides an ongoing view of how the company communicates its progress and priorities.
LifeVantage (Nasdaq:LFVN) will release third quarter fiscal 2026 results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026. A conference call for investors is scheduled for 2:30 p.m. MT / 4:30 p.m. ET that day.
Telephone dial-in numbers, replay details with confirmation code, and a simultaneous live webcast (archived ~30 days) are provided for investor access.
LifeVantage (Nasdaq: LFVN) received U.S. Patent No. 12,589,067 B2 (issued March 31, 2026) for its Healthy Glow Essentials Stack, covering compositions and methods pairing Protandim Nrf2 Synergizer and TrueScience Liquid Collagen.
The patent cites synergistic activation of cellular signaling genes and fibroblast study results supporting skin benefits and broader cellular-health effects, reflecting over three years of the company’s R&D work.
LifeVantage (Nasdaq: LFVN) concluded its three-day Momentum Academy in Las Vegas on April 20, 2026, focused on leadership, product innovation and Consultant empowerment.
Highlights: introduction of two limited-time AXIO flavors, a U.S. patent granted for the Healthy Glow Essentials Stack, renewed Clean Commitment packaging efforts, and a planned CEO transition with Steve Fife retiring April 30 and Terrence Moorehead joining August 5 (with Michael Beindorff as interim CEO).
LifeVantage (Nasdaq: LFVN) announced Terrence Moorehead will become President and CEO, and join the board, effective August 5, 2026. Mr. Moorehead brings 25+ years of direct‑selling and consumer products experience, including leading Nature’s Sunshine where revenue rose 45% and EBITDA 190%.
Steve Fife will retire effective April 30, 2026; an interim team will lead the company until Mr. Moorehead assumes the role.
LifeVantage (Nasdaq: LFVN) will participate in the Water Tower Research Insights Conference on Wednesday, April 15, 2026. Senior management — CEO Steve Fife, CSO Kristen Cunningham, and VP R&D Lisa Barnes — will present. The webcast begins at approximately 12:30 p.m. ET and is open access.
According to the company, investors can register via the investor relations website to access the live webcast and related materials.
LifeVantage (Nasdaq: LFVN) will expand into Portugal with a planned May 2026 launch, offering flagship nutrigenomic products nationwide and introducing its independent Consultant business opportunity.
Initial portfolio includes Protandim Nrf2, Protandim Nrf1, and TrueScience Liquid Collagen; enrollment inquiries directed to ptsupport@lifevantage.com.
LifeVantage (Nasdaq: LFVN) will participate in the Sidoti Small Cap Conference March 18-19, 2026. CEO Steve Fife and CFO Carl Aure will meet virtually with investors and present on March 19, 2026 at ~4:00 p.m. ET.
A live webcast of the presentation will be available on the company’s Investor Relations News & Events page.
LifeVantage (Nasdaq: LFVN) announced a quarterly cash dividend of $0.045 per share, payable March 16, 2026 to shareholders of record at the close of business on March 2, 2026. The Board approved the distribution as a return of capital to common shareholders.
LifeVantage (Nasdaq: LFVN) announced that Steve Fife, President and CEO, will retire in April 2026 after nine years at the company.
Fife will remain in his role during a transition while the Board conducts an extensive executive search and anticipates naming a new CEO in the coming months.
LifeVantage (Nasdaq: LFVN) reported Q2 fiscal 2026 results for the quarter ended Dec 31, 2025: revenue $48.9M (down 27.8% YoY, +2.9% sequential), net income $0.3M or $0.02 diluted, adjusted EPS $0.15, and adjusted EBITDA $3.9M. Gross margin was 74.0% with a $2.4M inventory obsolescence charge tied to MindBody GLP-1. Cash was $10.2M with no debt. The board approved a $60M share repurchase program and declared a $0.045 per-share cash dividend payable Mar 16, 2026. Fiscal 2026 guidance: revenue $185M–$200M; adjusted EBITDA $15M–$19M; adjusted EPS $0.60–$0.80.